Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21306627 | 0.86 | SCN9A (0.46) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL21307056 | 0.86 | SCN9A (0.46) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL29481962 | 0.84 | MAOB (0.42) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL21294962 | 0.84 | MAOB (0.42) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL29482018 | 0.84 | KDM1A (0.44) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL20063742 | 0.84 | MAOB (0.42) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL21306626 | 0.84 | MAOB (0.42) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL21294857 | 0.84 | KDM1A (0.44) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL29482052 | 0.84 | KDM1A (0.44) | KDM1AMAOBTACR1TAS1R3TAS1R1 | |
| SCHEMBL29481964 | 0.84 | MAOB (0.42) | KDM1AMAOBTACR1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-112041313-A | Pyridine-sulfonamide compounds and their use against pain and related conditions | 基因泰克公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | KDM1A 4612/4885MAOB 1656/4885TACR1 186/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | KDM1A 3431/4885MAOB 1125/4885TACR1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.